Wegovy for Teens: Eligibility, Trial Results and Parent Questions

Can teenagers take Wegovy?

Wegovy injection is indicated for weight reduction and maintenance in children aged 12 and older with obesity, alongside a reduced-calorie diet and increased physical activity.¹ That is different from offering a prescription to any teenager who wants to weigh less. A pediatric assessment needs to establish the diagnosis, suitability and a plan for care.

Elena Voss is a mother writing for mothers, not a treating clinician, and holds no medical license. Every clinical figure here is cited inline to its primary source, the trial or the FDA label, so you can check it. This is background reading, not medical advice.

This page is for parents preparing for that conversation. It does not recommend an adult weight-loss service for a child. The indication for the injection also does not make every semaglutide product or formulation an adolescent treatment. Bring the exact product name into the discussion rather than asking for “the same shot my friend takes.”

How is eligibility different from adult weight treatment?

Children's BMI is interpreted in relation to age and sex, rather than by simply applying the adult BMI cutoffs printed in many advertisements. The STEP TEENS trial enrolled adolescents using pediatric BMI-percentile criteria.² Ask the clinician to explain the growth chart and the clinical diagnosis in language your child can understand.

A useful appointment starts with the health problem, not a target appearance. Bring prior growth records, relevant diagnoses, medications and the questions your child wants answered. Ask how the proposed treatment fits with existing care and who will coordinate it if several clinicians are involved. Keep room for your child to describe their own concerns without turning the visit into a discussion conducted only between adults.

The current US label has separate pediatric injection maintenance instructions; its adult higher-dose and tablet pathways should not be imported into a teenager's plan.¹ Families should ask the prescribing clinician to explain the actual prescription rather than extrapolating from adult social media dosing charts.

What did STEP TEENS find?

STEP TEENS randomized 201 adolescents to weekly semaglutide or placebo, with lifestyle intervention in both groups. At 68 weeks, average BMI changed by minus 16.1% with semaglutide and plus 0.6% with placebo. At least 5% body-weight reduction occurred in 73% and 18%, respectively.^2,3

Those are group results under study conditions. BMI change and body-weight change are different endpoints: a headline that calls a 16.1% BMI reduction “16.1% weight loss” changes what was measured. The trial also does not tell a family exactly how long one child should remain on treatment or what their health will look like decades later.

Manufacturer funding is another relevant piece of context: Novo Nordisk funded the trial.² That does not erase a randomized comparison, but readers should know who supported the research. Ask what independent follow-up evidence is available and what important questions remain unanswered for your child's circumstances.

What about side effects and emotional wellbeing?

In STEP TEENS, gastrointestinal events were reported in 62% of semaglutide participants and 42% of placebo participants; gallstones were reported in five semaglutide participants and none receiving placebo.² These figures describe that trial, not the probability for a specific child. A discussion of benefit should include harms and the possibility of stopping.

Ask for a plan covering symptoms between visits, difficulty eating or drinking, and when the family should contact the team promptly. The product label contains contraindications and serious warnings; the clinician should review them against the child's medical and family history.¹ A reassuring advertisement is not a substitute for that review.

Also ask how the team discusses body image, bullying, food restriction and distress. Weight treatment should leave space to hear what the child is experiencing. Our eating-behavior evidence guide addresses why changes in appetite and a history of disordered eating deserve careful attention; it is background reading, not a pediatric assessment.

What should ongoing care include?

Before agreeing to a treatment, ask who will monitor progress and how often the family will be seen. Clarify who handles the prescription, who provides nutrition advice and how to reach the team if the medicine is unavailable. Ask how school schedules, sports and other commitments can be accommodated without turning food and weight into the center of family life.

Costs deserve their own conversation. Find out whether pediatric care and the medication are covered separately, what authorization is required and what happens if the insurer stops paying. Avoid assuming that an adult cash-price promotion applies to a child. An affordable first fill does not establish that follow-up or continued treatment is accessible.

Prepare a short list together: what the child hopes will improve, what worries them, which symptoms they would tell you about and what would make the plan feel unmanageable. Bring that list to the clinician. It can reveal a practical problem that a BMI number or a prescription form would miss.

What is established, and what remains uncertain?

The label establishes an adolescent obesity indication for the injection, and STEP TEENS provides randomized evidence of benefit and adverse events over its study period.^1,2 Neither establishes a guaranteed outcome, lifelong safety for every child or the suitability of an adult telehealth provider. The next step is a pediatric care discussion with a clear diagnosis, realistic expectations and an accountable follow-up plan.